Filing Flows › Krystal Biotech (KRYS) › How it makes money
How Krystal Biotech (KRYS) makes money
Krystal Biotech (KRYS) made $127M of revenue in the third quarter 2026 (Q3 2026), +30% from a year earlier. Of every dollar of revenue, 56¢ was left as operating profit, 50¢ was left as net earnings.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $127M | 100.0% |
| Operating profit | $71.1M | 55.9% |
| Income tax | $17.1M | 13.4% |
| Net earnings | $63.1M | 49.5% |
| Operating cash flow | $91.2M | 71.7% |
| Free cash flow | $90.3M | 70.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $127M | +30% |
| Q2 2026 | $119M | +24% |
| Q1 2026 | $116M | +32% |
| Q4 2025 | $107M | +18% |
| Q3 2025 | $97.8M | +17% |
| Q2 2025 | $96.0M | +37% |
| Q1 2025 | $88.2M | +95% |
From Krystal Biotech's 10-Q filed Nov 2, 2026 (on EDGAR).
Questions
How does Krystal Biotech make money?
Krystal Biotech (KRYS) made $127M of revenue in the third quarter 2026 (Q3 2026), +30% from a year earlier. Of every dollar of revenue, 56¢ was left as operating profit, 50¢ was left as net earnings.
What is Krystal Biotech's profit margin?
Net earnings were $63.1M, 49.5% of revenue, in the third quarter 2026; the operating margin was 55.9%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.